CORD-19:932bcdd2f6c6d487386e8bf983e4874387771be1 / 488143-488324 JSONTXT

{"target":"https://pubannotation.org/docs/sourcedb/CORD-19/sourceid/932bcdd2f6c6d487386e8bf983e4874387771be1","sourcedb":"CORD-19","sourceid":"932bcdd2f6c6d487386e8bf983e4874387771be1","text":"After 6 months of IFN-beta-1b 250 mcg treatment, patients with persisting disease activity were randomized to either continue on 250 mcg dose or receive an increased dose (375 mcg).","tracks":[{"project":"CORD-19-Sentences","denotations":[{"id":"T61653","span":{"begin":0,"end":181},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"attributes":[{"subj":"T61653","pred":"source","obj":"CORD-19-Sentences"}]},{"project":"CORD-19_Custom_license_subset","denotations":[{"id":"T102","span":{"begin":0,"end":181},"obj":"Sentence"}],"attributes":[{"subj":"T102","pred":"source","obj":"CORD-19_Custom_license_subset"}]}],"config":{"attribute types":[{"pred":"source","value type":"selection","values":[{"id":"CORD-19-Sentences","color":"#ad93ec","default":true},{"id":"CORD-19_Custom_license_subset","color":"#93ec93"}]}]}}